You are here: Home » PTI Stories » National » News
Business Standard

Glenmark gets tentative nod from USFDA for Fingolimod capsules

Press Trust of India  |  New Delhi 

Drug firm Glenmark Pharmaceuticals today said it has got tentative approval from the United States Food and Drug Administration (USFDA) for Fingolimod capsules.

These capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis.



"Glenmark Pharmaceuticals has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules of Pharmaceuticals Corp," Glenmark said in a filing.

As per IMS Health sales data for the 12 month period ended January 2017, Gilenya capsules 0.5 mg had annual sales of approximately USD 2.03 billion, it added.

of Glenmark Pharmaceuticals were trading 0.78 per cent down at Rs 879.45 apiece on

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Glenmark gets tentative nod from USFDA for Fingolimod capsules

Drug firm Glenmark Pharmaceuticals USA today said it has got tentative approval from the United States Food and Drug Administration (USFDA) for Fingolimod capsules. These capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis. "Glenmark Pharmaceuticals USA has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules of Novartis Pharmaceuticals Corp," Glenmark said in a BSE filing. As per IMS Health sales data for the 12 month period ended January 2017, Gilenya capsules 0.5 mg had annual sales of approximately USD 2.03 billion, it added. Shares of Glenmark Pharmaceuticals were trading 0.78 per cent down at Rs 879.45 apiece on BSE. Drug firm Glenmark Pharmaceuticals today said it has got tentative approval from the United States Food and Drug Administration (USFDA) for Fingolimod capsules.

These capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis.

"Glenmark Pharmaceuticals has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules of Pharmaceuticals Corp," Glenmark said in a filing.

As per IMS Health sales data for the 12 month period ended January 2017, Gilenya capsules 0.5 mg had annual sales of approximately USD 2.03 billion, it added.

of Glenmark Pharmaceuticals were trading 0.78 per cent down at Rs 879.45 apiece on

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Glenmark gets tentative nod from USFDA for Fingolimod capsules

Drug firm Glenmark Pharmaceuticals today said it has got tentative approval from the United States Food and Drug Administration (USFDA) for Fingolimod capsules.

These capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis.

"Glenmark Pharmaceuticals has been granted tentative approval by the USFDA for Fingolimod capsules, 0.5 mg, the generic version of Gilenya capsules of Pharmaceuticals Corp," Glenmark said in a filing.

As per IMS Health sales data for the 12 month period ended January 2017, Gilenya capsules 0.5 mg had annual sales of approximately USD 2.03 billion, it added.

of Glenmark Pharmaceuticals were trading 0.78 per cent down at Rs 879.45 apiece on

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

image
Business Standard
177 22